CME Activities

CLICK ON STATES TO SEE LOCAL AND NATIONAL CME PROGRAMS.
(since they are not all just grand rounds)

ONLINE ACTIVITIES

Jul
1
Thu
New Targeted Therapies for Improving Cholesterol and CV Outcomes in Patients with Familial Hypercholesterolemia
Jul 1 2021 @ 7:12 pm – Jan 28 2023 @ 8:12 pm

New Targeted Therapies for Improving Cholesterol and CV Outcomes in Patients with Familial Hypercholesterolemia

View Activity

FACULTY

Robert S. Rosenson, MD, FACC, FACP, FAHA, FESC, FCCP, FNLA
Director of Metabolism and Lipids
Mount Sinai Health System
Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
New York, NY

PROGRAM OVERVIEW

This enduring activity is focused on the team involved in the management of patients with familial hypercholesterolemia.


LEARNING OBJECTIVES

  • Develop tailored, intensified, lipid-lowering regimens based on clinical guidance, individual patient risk factors, comorbidities, and prior treatment for patients with familial hypercholesterolemia (FH)
  • Interpret evidence from clinical trials assessing therapies for the treatment of patients with FH, including long-term cardiovascular outcomes
  • Prepare treatment plans that account for genetic aberrations impacting the activity of low-density lipoprotein receptors in patients with FH

TARGET AUDIENCE

This activity is intended for lipidologists, cardiologists, and other healthcare professionals involved in the management of patients with familial hypercholesterolemia (FH).


ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with familial hypercholesterolemia.
Credits: 1.0 ANCC Contact Hour(s)


ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF FINANCIAL RELATIONSHIPS

Dr. Rosenson discloses the following:

  • Research grants to his institution from Amgen, Amyrt Pharma, Arrowhead, NIH, Novartis, and Regeneron
  • Serving on advisory boards for Amgen, C5, CVS Caremark, Novartis, Regeneron, and 89bio
  • Receiving honoraria for non-promotional speaking from Amgen, Kowa, and Regeneron
  • Royalties from UpToDate, Inc.
  • Received consulting fees from Amgen, Amyrt, C5, CVS caremark, Novartis and Regeneron
  • Receipt of intellectual property/Patent Holder from Biocellular inflammatory pathways, Immunothrombotic mechanisms

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete and submit the evaluation form to Med Learning Group.

You will receive your certificate after the enduring activity.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: June 30, 2021

EXPIRATION DATE: June 30, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
2
Fri
New Targeted Therapies for Improving Cholesterol and CV Outcomes in Patients with Familial Hypercholesterolemia
Jul 2 2021 @ 8:18 am – Jan 29 2023 @ 9:18 am

New Targeted Therapies for Improving Cholesterol and CV Outcomes in Patients with Familial Hypercholesterolemia

View Activity

FACULTY


Samuel Gidding, MD
Genomic Medicine Institute
Geisinger Medical Center
Danville, PA

PROGRAM OVERVIEW

This enduring activity is focused on the team involved in the management of patients with familial hypercholesterolemia.


LEARNING OBJECTIVES

  • Use strategies to detect genetic aberrations impacting the activity of LDL-Rs early in pediatric patients with familial hypercholesterolemia (FH)
  • Develop tailored intensified lipid-lowering regimens based on clinical guidance, individual pediatric patient risk factors, comorbidities, and prior treatment for patients with FH
  • Interpret evidence from clinical trials assessing therapies for the treatment of pediatric patients with FH including long-term CV outcomes

TARGET AUDIENCE

This activity is intended for pediatric cardiologists, lipidologists, cardiologists, and other healthcare professionals involved in the management of patients with FH.


ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with familial hypercholesterolemia.
Credits: 1.0 ANCC Contact Hour(s)


ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF FINANCIAL RELATIONSHIPS

Dr. Gidding discloses the following:

  • Consultant for Esperion (bempedoic acid clinical trials in children), and Silence Therapeutics (Scientific Advisory Board regarding Lp(a))

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Amanda Jenkins, Program Coordinator for Med Learning Group has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete and submit the evaluation form to Med Learning Group.

You will receive your certificate after the enduring activity.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: July 22, 2021

EXPIRATION DATE: July 22, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
3
Sat
New Targeted Therapies for Improving Cholesterol and CV Outcomes in Patients with Familial Hypercholesterolemia
Jul 3 2021 @ 8:18 am – Jan 30 2023 @ 9:18 am

New Targeted Therapies for Improving Cholesterol and CV Outcomes in Patients with Familial Hypercholesterolemia

View Activity

FACULTY


Joseph Saseen, PharmD
Associate Dean for Clinical Affairs and Professor of Medicine
Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Aurora, CO

PROGRAM OVERVIEW

This enduring activity is focused on the team involved in the management of patients with familial hypercholesterolemia.


LEARNING OBJECTIVES

  • Develop tailored intensified lipid-lowering regimens based on clinical guidance, individual patient risk factors, comorbidities, and prior treatment for patients with FH
  • Interpret evidence from clinical trials assessing therapies for the treatment of patients with FH including long-term CV outcomes
  • Assess the unique treatment needs of patients with FH and increased risk for ACVD, including expanded formulary options such as allowing the highest doses of statins, more potent statins, newly approved drugs, and unique combination therapies

TARGET AUDIENCE

This activity is intended for managed care professionals, pharmacists, physicians, nurses, and other healthcare professionals involved in the management of patients with familial hypercholesterolemia (FH).


ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with familial hypercholesterolemia.
Credits: 1.25 ANCC Contact Hour(s).


ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour(s) of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF FINANCIAL RELATIONSHIPS

Dr. Sasseen has no financial relationships to disclose.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Amanda Jenkins, Associate Program Manager for Med Learning Group has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete and submit the evaluation form to Med Learning Group.

You will receive your certificate after the enduring activity.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: August 30, 2021

EXPIRATION DATE: August 30, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
4
Sun
Improving Cholesterol and Outcomes in Patients with Familial Hypercholesterolemia: An Update on New Medical Therapy and Lipid Apheresis
Jul 4 2021 @ 8:18 am – Jan 31 2023 @ 9:18 am

Improving Cholesterol and Outcomes in Patients with Familial Hypercholesterolemia: An Update on New Medical Therapy and Lipid Apheresis

View Activity

FACULTY


Patrick M. Moriarty, MD
Professor of Medicine
Kansas University Medical Center
Director of Clinical Pharmacology
The University of Kansas Health System
Kansas City, KS

PROGRAM OVERVIEW

This enduring activity is focused on the team involved in the management of patients with familial hypercholesterolemia.


LEARNING OBJECTIVES

  • Develop tailored intensified lipid-lowering regimens based on clinical guidance, individual patient risk factors, comorbidities, and prior treatment for patients with familial hypercholesterolemia (FH)
  • Interpret evidence from clinical trials assessing therapies for the treatment of patients with FH including long-term CV outcomes
  • Assess the unique treatment needs of patients with FH and increased risk for ACVD, including expanded formulary options such as allowing the highest doses of statins, more potent statins, newly approved drugs, and unique combination therapies

TARGET AUDIENCE

This activity is intended for managed care professionals, pharmacists, physicians, nurses, and other healthcare professionals involved in the management of patients with familial hypercholesterolemia (FH).


ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


CNE CONTENT REVIEW

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose
Staff Planners and Managers
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with familial hypercholesterolemia.
Credits: 1.0 ANCC Contact Hour(s)


ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF FINANCIAL RELATIONSHIPS

Dr. Moriarty has no financial relationships to disclose.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Amanda Jenkins, Associate Program Manager for Med Learning Group has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete and submit the evaluation form to Med Learning Group.

You will receive your certificate after the enduring activity.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: September 20, 2021

EXPIRATION DATE: September 20, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Feb
23
Wed
New Optimal Low-density Lipoprotein Cholesterol Reductions in Patients with Atherosclerotic Cardiovascular Disease: Maximizing Clinical Benefit within the Department of Veterans Affairs
Feb 23 2022 @ 7:59 pm – Feb 23 2023 @ 8:59 pm

New Optimal Low-density Lipoprotein Cholesterol Reductions in Patients with Atherosclerotic Cardiovascular Disease: Maximizing Clinical Benefit within the Department of Veterans Affairs

 

View Activity

PROGRAM CHAIR AND SPEAKING FACULTY

Christie M Ballantyne, MD, FACP, FACC
Chief, Section of Cardiology
Chief, Section of Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Professor of Medicine, Molecular & Human Genetics, and Molecular Physiology & Biophysics
Baylor College of Medicine
Houston, TX

PROGRAM OVERVIEW

This activity is designed to help lipidologists, cardiologists, and other healthcare professionals involved in the management of US veterans with familial hypercholesterolemia (FH) to improve cholesterol and cardiovascular outcomes for veteran patients.


TARGET AUDIENCE

This activity is intended for lipidologists, cardiologists, and other healthcare professionals involved in the management of US veterans with familial hypercholesterolemia (FH).


LEARNING OBJECTIVES

On completing the program, attendees should be able to:

  • Interpret evidence from clinical trials evaluating the efficacy and safety of PCSK9 inhibitors used to lower persistently elevated levels of LDL-C
  • Assess clinical trial-derived evidence suggesting that PCSK9 inhibitors can reduce the risk for developing ASCVD in patients with persistently elevated levels of LDL-C including those with FH
  • Formulate individualized management plans for US veterans with FH that include the use of PCSK9 inhibitors towards the goal of lowering LDL-C levels and associated risk of ASCVD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses who are involved in the healthcare of US veterans with familial hypercholesterolemia.
Credits: 1.0 ANCC Contact Hour.


ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosure
Christie M Ballantyne, MD, FACP, FACC Dr. Ballantyne reports that he serves as a consultant for Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer:

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Debra Gordon, MS, Medical Director for Med Learning Group has nothing to disclose.
  • Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures
  2. Participate in the enduring activity.
  3. Complete posttest and evaluation form online.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

RELEASE DATE: February 23, 2022

EXPIRATION DATE: February 23, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Scroll to Top